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Abstract
Patients with severe asthma have a greater risk of asthma-
related symptoms, morbidities, and exacerbations. Moreover, 
healthcare costs of patients with severe refractory asthma 
are at least 80% higher than those with stable asthma, mainly 
because of a higher use of healthcare resources and chronic 
side effects of oral corticosteroids (OCS). The advent of new 
promising biologicals provides a unique therapeutic option 
that could achieve asthma control without OCS. However, 
the increasing number of available molecules poses a new 
challenge: the identification and selection of the most 
appropriate treatment. Thanks to a better understanding of 
the basic mechanisms of the disease and the use of predictive 
biomarkers, especially regarding the Th2-high endotype, it is 
now easier than before to tailor therapy and guide clinicians 
toward the most suitable therapeutic choice, thus reducing the 
number of uncontrolled patients and therapeutic failures. In this 
review, we will discuss the different biological options available 
for the treatment of severe refractory asthma, their mechanism 
of action, and the overlapping aspects of their usage in clinical 
practice. The availability of new molecules, specific for different 
molecular targets, is a key topic, especially when considering 
that the same targets are sometimes part of the same 
phenotype. The aim of this review is to help clarify these doubts, 
which may facilitate the clinical decision-making process and 
the achievement of the best possible outcomes.
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eosinophils, inflammation, phenotypes.
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Introduction
Patients with severe asthma have an increased risk of asthma-
related symptoms, morbidities, and exacerbations.1,2 Moreover, 
healthcare costs of patients with severe refractory asthma are 
at least 80% higher than those with stable asthma because 
of a higher use of resources.3,4 Approximately, up to 30% of 
patients with refractory asthma still require regular use of 
oral corticosteroids (OCS).5 Prolonged use of OCS may lead to 
several side effects such as osteoporosis, fracture, infections, 
obesity, symptomatic coronary artery disease, avascular 
necrosis, stroke, cataract, glucose metabolism changes, and 
skin thinning.6 In addition, there is an obvious concern about 
the adverse effects, especially growth, induced by OCS in 
children.7 The potential side effects of OCS heavily affect 
patients’ quality of life and sustain a big economical burden.
The advent of new promising biological therapies provides a 
strategy to avoid OCS damage and to improve global asthma 
control. For several years, the only available biologic therapy 
has been omalizumab, a monoclonal antibody (mAb) that 
targets immunoglobulin E (IgE) and is used for a specific 
subpopulation of patients with uncontrolled IgE-mediated 
allergic asthma. Recently, new drugs and nonpharmacologic 
options, such as anti-interleukin (IL)-5 mAbs, anti-IL-4/IL-13, and 
bronchial thermoplasty, are available as upcoming options, 
supported by encouraging results for patients not eligible or 
not responsive to omalizumab (Table 1). Due to the number of 
available treatment alternatives, the identification of the right 
drug for the right patient represents a key aspect of treatment, 
which can be implemented by new biomarkers reflecting an 
underlying disease mechanism, in addition to the correct use of 
those already available.
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In this review, the management of available therapies and the 
overlapping aspects of some of those treatments as well as 
their application in clinical practice will be discussed. The future 
availability of new molecules that are specific for different 
targets is a key topic, especially when considering that the 
same targets are sometimes part of the same phenotype. It is 
important to address and clarify some of these aspects, which 
may further facilitate the clinical decision-making process to 
identify the most successful treatment option and obtain the 
best possible outcomes.
Methods
For this review, a search strategy based on validated keyword 
filters was devised to select articles regarding severe asthma 
and its management. In detail, a selective search on medical 
databases (in particular PubMed and Medline) was carried 
out up to February 2018, and research papers, international 
guidelines, recommendations, position papers, systematic 
reviews, and Cochrane meta-analyses relevant to the topic 
have been considered. The search strategy was based on 
the following keywords: inflammation, asthma phenotypes, 
asthma endotypes, T2-low and T2-high subtypes, IgE, 
eosinophils, cytokines, IL-5, IL-4, IL-13, and costs. A total 
of 245 potential papers were identified in the first search 
through databases, and 115 of these were considered eligible. 
Only original studies with human subjects were considered, and 
only full texts were included among those potentially relevant. 
Case reports and purely descriptive studies were excluded.
Severe asthma treatments:  
Th2 versus non-Th2
Asthma is recognized as a complex condition with differences in 
severity, natural history, comorbidities, and treatment response. 
A longstanding debate in the asthma field is whether asthma is 
a single disease with a variable presentation, or several diseases 
that have variable airflow obstruction as a common feature.8 
Therefore, different definitions have been proposed based 
on the ‘observable characteristics’ – the phenotypes – which 
describe clinical, physiological, morphologic, and biochemical 
characteristics as well as the response to different treatments.9 
However, even if clinically relevant, phenotypes do not provide 
any insight on the underlying disease mechanism. Thus, in relation 
to asthma heterogeneity, the term ‘endotype’ has recently been 
introduced to describe ‘a subtype of a condition defined by a 
unique or distinctive functional or pathophysiologic mechanism’.10 
Currently available treatments and most of the upcoming 
ones are directed to the inflammatory Th2 endotype that 
drives the inflammation in about 50% of asthma patients.6 
The mechanisms underlying the dysregulation of innate and 
adaptive Th2 immunity in severe asthma have been intensively 
analyzed in a recent review.11 Cytokines, chemokines, and 
mediators involved in the Th2-signaling and inflammatory 
Table 1. Biodrug options for severe asthma.
Drug
(Administration)
Regimen Target population Clinical outcomes
Anti-IgE Omalizumab
(Subcutaneous)
From 75 mg up 
to 1200 mg every 
2/4 weeks
Early onset asthma.
Serum total IgE levels 30 ≤ IgE ≤ 
1500 IU/mL
Positive skin prick test or specific 
serum IgE for perennial allergens
Confirmed long-term efficacy both 
in adults and in children, antiviral 
effect, prevention of seasonal 
exacerbations
Anti-IL-5
Mepolizumab
(Subcutaneous)
100 mg every  
4 weeks
Eosinophilic asthma ≥300 cells/µL, 
NP – CSWNP§, late onset asthma 
Excellent safety profile, 
demonstrated clinical effect, and 
steroid-sparing effect
Benralizumab
(Subcutaneous)
30 mg every  
4 weeks for the 
first 3 doses, then 
every 8 weeks
Eosinophilic asthma ≥300 cells/µL, 
NP – CSWNP§, late onset asthma 
High affinity for IL-5 receptor and 
ADCC activity, eosinophils total 
tissue depletion, improvement of 
pulmonary function
Reslizumab
(Intravenous)
3 mg kg−1 every  
4 weeks
Eosinophilic asthma ≥300 cells/µL, 
NP – CSWNP§
Personalized dosage and 
improvement of pulmonary 
function
Anti-IL-4/
IL-13
Dupilumab
(Subcutaneous)
300 mg every  
4 weeks
Eosinophilic asthma ≥150–300 
cells/µL, aspirin-exacerbated 
respiratory disease (AERD)*
Significant steroid-sparing effect 
and improvement of pulmonary 
function
*Aspirin-exacerbated respiratory disease (AERD): defined by a physician diagnosis of asthma, chronic rhinosinusitis with nasal 
polyposis, and a convincing clinical history of nonsteroidal anti-inflammatory drug (NSAID) sensitivity.
§CSwNP, chronic sinusitis with nasal polyposis; NP, nasal polyposis.
ADCC, antibody-mediated cell cytotoxicity; IgE, immunoglobulin E; IL, interleukin.
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promising results in early human trials.13 Moreover, recent data 
are increasingly confirming the role of Th17 cells and IL-17: 
neutralization of IL-4 and/or IL-13 resulted in increased Th17 
cells and neutrophilic inflammation in the lung, which confirms 
that Th2 and Th17 inflammatory pathways are reciprocally 
pathways are almost all targeted by the available mAbs and 
other mediators will be targeted in the next future (Table 2).12
Regarding the neutrophilic non-Th2 endotype, currently 
there are not effective therapeutic options, even if some 
chemo-attractant antagonists for neutrophilis have shown 
Table 2. Non-Th2 and Th2 strategies under investigation.
Endotype Target Therapy  
Th2 IgE Omalizumab
Available
IL-5 Mepolizumab
Th2 IL-5 Reslizumab
Under investigation
IL-5Rα Benralizumab
IL-13Rβ Lebrikizumab
IL-4α Dupilumab
IL-13 Tralokinumab
GATA3 GATA3 DNAzyme
Non-Th2 Airways smooth muscle Bronchial termoplasty Available
TSLP Tezepelumab
Under investigation
PDG2 antagonist Fevipiprant
ILC2 Anti-CRTH2
Neutrophils Anti-CXCR2
CRTH2, chemoattractant receptor-homologous molecules expressed on Th2 cells; CXCR2, CXC chemokine receptor 2;  
IgE, immunoglobulin E; IL, interleukin; ILC2, type II innate lymphoid cells; PDG2, prostaglandin D2; Th, T helper 2;  
TSLP, thymic stromal lymphopoietin.
Figure 1. Inflammatory pathway in asthma.
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IFNγ, interferon gamma; IL, interleukin; ILC2, type II innate lymphoid cells; 
TH, T helper; TSLP, thymic stromal lymphopoietin.
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regulated in asthma (Figure 1).14 Other studies have highlighted 
the role of Group 2 innate lymphoid cells (ILC2s) in asthma 
pathogenesis and regulation of inflammation.15 This enormous 
progress in understanding the inflammatory pathways could 
pave the way to the development of non-Th2 endotype target 
drugs in the next future (Table 2).
Anti-IgE approach
In IgE-mediated asthma, allergens exposure, IgE antibodies, 
and their binding to high-affinity (FcεRI) and low-affinity 
(FcεRII or CD23) receptors on the surface of effector cells 
(mast cells and basophils) induce degranulation and release 
of cytokines and inflammatory mediators, which leads to the 
bronchoconstriction associated with asthma exacerbations.16
Omalizumab is a murine mAb that has been used in clinical 
practice since 2003 for the treatment of severe allergic 
refractory asthma in patients with serum IgE levels ranging 
between 30 and 1500 IU/mL. This mAb is the result of a somatic 
cell hybridization method and is able to bind to FcεRI and FcεRII 
receptors of basophils, dendritic cells, and mast cells.17
In the past decade, studies have confirmed the efficacy and 
safety of omalizumab, in terms of significant reduction in the 
frequency of asthma exacerbations (up to 50%), quality of life 
(QoL) improvement, and a significant steroid-sparing effect.18 
This mAb showed a good efficacy profile even in non-allergic 
asthma,19 which can be explained by the possible existence of 
a local IgE production without systemic sensitization.20 Recent 
studies have confirmed its effectiveness in pediatric patients 
with refractory asthma,21 mainly in the prevention of seasonal 
exacerbations, thanks to the ability of omalizumab to restore 
interferon-α response to rhinoviruses.22 
According to the available evidence, omalizumab treatment 
should be continued without suspension, as the IgE levels 
and the number of FcεRI receptors increase 3–4 weeks after 
its suspension, resulting in a worsening of asthma control, 
especially in patients with higher levels of eosinophilia, 
periostin, and fractional exhaled nitric oxide (FeNO).23 In fact, 
the presence of these biomarkers seems to be related to a 
better response to omalizumab, but also to a more rapid loss 
of its effect after suspension, as shown in XPORT and EXTRA 
studies.23,24 The prevention of exacerbations by omalizumab 
was greater in the presence of higher eosinophil levels, which 
represents an overlapping aspect between anti-IgE and anti-
IL-5 mAbs. In a recent pooled analysis from two pivotal phase 
3 trials, the authors found a better omalizumab response in 
patients with peripheral blood eosinophils levels ≥300 cells/
µL.25 In this subgroup, the treatment with omalizumab reduced 
exacerbations by 67% versus a 45% reduction of exacerbations 
in patients with values <300 cells/µL. However, greater 
disease severity, history of emergency asthma treatment, 
hospitalization, forced expiratory volume in 1 second (FEV1), 
% predicted, inhaled corticosteroids (ICS) dose, and long-
acting beta-agonists (LABA) use, were associated with a 
greater reduction in exacerbation by omalizumab. These data 
suggested that the preventive benefit may have been more 
related to disease severity, rather than to blood eosinophilia. 
A very recent retrospective real-life study conducted in France 
on 872 adult and pediatric patients with severe allergic asthma 
(STELLAIR) has come to different conclusions.26 In this study, 
the response rate was calculated according to blood eosinophil 
count measured in the year prior to omalizumab treatment 
start. According to clinical evaluation, 67.2% of adults and 77.2% 
of minors were responders, while 71.1% of adults and 78.5% 
of minors had a ≥40% reduction in the exacerbation rate. In 
adults, the response rate for combined criteria was 58.4% for 
blood eosinophils ≥300 cells/µL and 58.1% for blood eosinophils 
<300 cells/µL. These data suggested that omalizumab response 
is unrelated to the level of blood eosinophilia, and therefore 
this biomarker should not be taken into consideration when 
choosing omalizumab as a treatment option.
Therefore, the correct selection of the patient for omalizumab 
implies not only a favorable response in the short term, but also 
an increase of clinical efficacy in the long term (up to 9 years of 
follow-up),27 with a possible favorable cost-effectiveness profile 
in patients with refractory asthma, if correctly selected.28
Anti-IL-5, anti-eosinophils, and the 
possible overlap with anti-IgE
Mepolizumab was the first biologic available for severe 
eosinophilic asthma. It is a humanized non-glycosylated IgG1 
antibody blocking IL-5 and preventing the binding of IL-5 to 
its receptor. The first studies investigated the application of 
mepolizumab in diseases other than asthma, such as idiopathic 
hypereosinophilic syndrome and eosinophilic granulomatosis 
with polyangiitis (EGPA),29 and demonstrated a significant 
reduction in the use of OCS and a better control of the disease. 
The dose of mepolizumab in EGPA is 300 mg instead of 100 
mg for asthma. Early studies on asthma failed to reach the 
expected outcomes, as mepolizumab was ineffective in terms 
of improvement of respiratory function parameters (bronchial 
hyperresponsiveness, FEV1, peak expiratory flow – PEF) and 
reduction of exacerbation.30,31 However, several studies 
underlined the presence of a bias in patients’ recruitment, as 
they had not been properly stratified and selected according 
to their blood eosinophils and asthma severity. Subsequently, 
the DREAM, MENSA, and SIRIUS registrative randomized clinical 
trials (RCTs) showed the ability of this drug to significantly 
improve the control of asthma with a significant steroid-sparing 
effect in patients with severe asthma with blood eosinophils 
>300 cells/μL.32–34 The MUSCA trial has confirmed that 
mepolizumab significantly improved the health-related QoL 
with an early improvement of pre-bronchodilator FEV1 values 
sustained up to week 24.35 
A post hoc analysis of DREAM and MENSA RCTs showed that 
baseline blood eosinophil count represents a biomarker 
predictive of mepolizumab clinical efficacy.36 The authors 
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highlighted clinically relevant reductions in exacerbation rate 
in patients with a count of 150 cells/μL or more at baseline. 
Notably, this biomarker, although not specific, could lead to 
better patients’ selection, especially for those who are likely to 
achieve important clinical improvement with mepolizumab. In 
addition, the drug demonstrated an excellent safety profile and 
a long-lasting and stable effect, as highlighted by the COSMOS 
study.37 
Another anti-IL-5 is reslizumab, a humanized IgG4k mAb 
with high affinity for IL-5. This mAb addresses patients with 
uncontrolled eosinophilic asthma and blood eosinophil level 
>400 cells/μL, showing a meaningful reduction of sputum 
eosinophil count, improvement in QoL, FEV1, and reduction of 
exacerbation rate.38,39 
A post hoc analysis of two identical pivotal trials (Studies 3082 
and 3083) showed that patients with asthma, chronic sinusitis 
with nasal polyposis (CSwNP), and higher blood eosinophilia 
level (400 cells/μL) treated with reslizumab had 83% reduction 
of the annual rate of exacerbations compared to an overall 
reduction of 54%.40 These data confirm a major clinical benefit 
of anti-IL-5 treatment in patients with higher eosinophilia levels 
and CSwNP. In an open-label extension trial, 1051 patients 
received intravenous (IV) 3.0 mg/kg reslizumab up to 2 years, 
with a good safety profile and sustained long-term efficacy in 
terms of lung function improvements and asthma control.41 
These results reinforce the evidence of long-term safety and 
efficacy in anti-IL-5 mAbs.
A practical limitation of this drug may be the IV administration 
route, as it implies the availability of a venous access, and the 
infusion over 20–50 minutes. Currently, the above-mentioned 
administration route and dosage are the only ones approved by 
Food and Drug Administration (FDA) and European Medicines 
Agency (EMA). However, recent data showed that a weight-
adjusted dosage represents a potential added value, especially 
in overweight or obese patients. One study compared the 
response to weight-adjusted IV reslizumab in 10 prednisone-
dependent patients with asthma who were previously treated 
with 100 mg mepolizumab subcutaneous (SC).42 Reslizumab 
was shown to further reduce airway eosinophilia compared to 
mepolizumab SC, with a concomitant improvement in asthma 
control. Two ongoing phase 3 RCTs are evaluating the efficacy 
of reslizumab SC (ClinicalTrials.gov identifier: NCT02452190 
and NCT02501629) and a phase 2–3 study is investigating 
the monthly infusion of 3 mg/kg IV reslizumab for 4 months 
in patients with prednisone-dependent eosinophilic asthma 
previously treated with another IL-5 antagonist (mepolizumab) 
administered subcutaneously (ClinicalTrials.gov identifier: 
NCT02559791).
Benralizumab is a IgA1 mAb that binds the epitope on the 
α-subunit of the IL-5 receptor. It reduces blood eosinophils and 
their precursors through a completely different mechanism 
compared to other IL-5 antagonists, based on the induction of 
antibody-mediated cell cytotoxicity (ADCC).43,44 The constant 
region (Fc) of benralizumab is afucosylated, leading to a higher 
affinity for the Fc-gamma III (FcγRIIIa) receptor on the surface 
of mast cells, basophils, and natural killer cells. Through the 
last, it induces ADCC on eosinophils and basophils.45 The result 
is an almost complete depletion of eosinophils in sputum and 
tissues (90% and 96%, respectively), as well as a total depletion 
in the bone marrow and in the blood.46 In phase 1 and 2 
randomized controlled trials, including patients with severe 
and peripheral eosinophilic asthma (eosinophils > 300 cells/μL),  
SC benralizumab showed excellent results, especially in terms 
of reducing inflammatory mediators, as well as causing a 
significant reduction of blood eosinophils.47–49 Furthermore, 
different from other anti-IL-5 treatments, benralizumab is 
independent of circulating IL-5 levels, which tend to increase 
during asthma exacerbations. The drug is also insensitive to 
the effect of other cytokines such as IL-3 and GM-CSF, due to 
the profound depletion of eosinophils.44 All these findings 
have led to highly promising results in terms of reduction of 
exacerbations and average dose of OCS, with a response already 
evident after a single dose. The drug is administered every 4 
weeks for the first three doses, then every 8 weeks thereafter.50
Data from the ZONDA trial substudy showed a tissue depletion 
of eosinophils induced by benralizumab greater than other 
anti-IL-5.51 In addition, the effect of benralizumab-based ADCC 
could overcome the problem of the immune complex formation 
between mepolizumab and IL-5, which may serve as an IL-5 
reservoir and thus determine a partial response to treatment 
(underdosing), as reported by some researchers.52 The effect 
of benralizumab on the improvement of FEV1 is evident, even 
in patients with fixed airflow obstruction (FAO) and obesity, 
as highlighted by the post hoc analysis of the studies SIROCCO 
and CALIMA.53,54 Even if at different levels, a few studies have 
provided evidence of the benefit of the mABs on the steroid-
sparing effect, as evidenced when comparing the data from the 
ZONDA50 and SIRIUS34 RCTs on benralizumab and mepolizumab, 
respectively. The former showed that the two benralizumab 
dosing regimens (30 mg administered subcutaneously either 
every 4 weeks or every 8 weeks – with the first three doses 
administered every 4 weeks) significantly reduced the median 
final oral glucocorticoid doses from baseline by 75%, as 
compared with a reduction of 25% in the oral glucocorticoid 
doses in the placebo group (p<0.001 for both comparisons). On 
the other hand, the latter showed that the median percentage 
reduction from baseline in the glucocorticoid dose was 50% 
in the mepolizumab group (100 mg administered SC every 4 
weeks for 20 weeks), as compared with no reduction in the 
placebo group (p=0.007). Even if direct comparative studies 
are needed, this may suggest a greater effectiveness of 
benralizumab as compared to the direct competitor.
Moreover, the pre-filled syringe and the administration every 
8 weeks reinforce the drug profile in terms of compliance 
and usability. In accordance with these findings and on the 
clinical evidence, the baseline factors that positively impact 
on response to benralizumab are a higher dose of OCS, 
frequent asthma exacerbations, nasal polyposis, and forced 
vital capacity (FVC) <65% predicted.55 The sustained tissue 
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depletion of eosinophils induced by benralizumab may raise 
some concerns regarding the theoretical risk of tumors, 
infections, and autoimmune diseases. However, several data 
have confirmed that the absence of eosinophils from mammals 
is not associated with any pathology.56 The observation that 
eosinophil-deficient mice do not show any characteristic 
syndrome or global health issues strongly supports that under 
usual laboratory conditions eosinophil does not play a critical 
role in maintaining mammalian well-being. On the opposite 
side, the neutrophils deficiency is typically associated with 
more frequent bacterial infections.57 The available data suggest 
that current anti-eosinophil therapies are safe, although long-
term studies are needed to confirm their safety. 
The possibility of overlapping target population between 
omalizumab and anti-IL-5, shown in up to 37% of cases,58 is a 
critical topic (Figure 2). It is therefore essential to understand 
the responder profile of each of the two options, and to identify 
the potential candidates to a treatment switch, although 
in the absence of head-to-head comparative studies up to 
now. Meta-analysis data show that the efficacy of omalizumab 
and mepolizumab is similar in terms of clinical outcomes.59 
Unfortunately, the heterogeneity of selection criteria and the 
absence of biomarkers specifically predictive of treatment 
response make the treatment choice a difficult task.
A post hoc analysis aiming to evaluate the effect of 
mepolizumab in patients with severe eosinophilic asthma 
previously treated with omalizumab showed how high 
levels of IgE and the presence of atopy does not reduce the 
effectiveness of anti-IL-5.60 Patients with severe eosinophilic 
asthma responded positively to mepolizumab regardless of the 
prior use of omalizumab, thus supporting the switch between 
anti-IgE and anti-IL-5, in case of ineffectiveness of the former, as 
a potentially effective intervention.
Blocking IL-4 and IL-13: 
role of dupilumab
IL-4 and IL-13 are pleiotropic Th2 cytokines, which share a 
common receptor, IL-4Rα, and a common pathway. Dupilumab 
is a new mAb that inhibits the pro-inflammatory effect of 
these two cytokines through its interaction with the IL-4 α 
subunit of the IL-4 receptor.61 Recent studies investigating 
dupilumab administered SC at doses ranging from 100 to 300 
mg showed a significant decrease in the rate of exacerbations, 
an improvement of asthmatic symptoms and pulmonary 
function.62 A reduction of the inflammatory biomarkers related 
to the activity of Th2 lymphocytes (TARC levels, eotaxin-3, 
FeNo) without modifications in the eosinophils count (±300 
cells/μL) was also noticed.63,64 A very recent phase 3 RCT 
(liberty asthma venture) demonstrated that the greatest 
efficacy of dupilumab was observed in patients with type 2 
profile (blood eosinophil count at baseline ≥150 per cells/μL 
and baseline FeNO ≥ 25 ppb). Among patients with a blood 
eosinophil count of >300 cells/μL, treatment with dupilumab 
Figure 2. Severe asthma endotype serving for the correct therapeutic choice.
Th2-High 
Bronchial
thermoplasty
Th2-Low
IgE Eosinophils
>300 cells/µl >400 cells/µl
Azithromycin 
Omalizumab
Mepolizumab 
NeutrophilicPaucigranulocytic
Endotype Therapeutic
target 
Approved therapy
Injectable
Non  pharmacological
option 
Oral
Dupilumab Reslizumab 
Benralizumab 
Therapy in clinical
development
150 cells/µl
FeNo 25≥ppb
IgE, immunoglobulin E; Th2, T helper 2.
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resulted in a 65.8% reduction of the severe exacerbation rate 
compared to the placebo group.65 In another study (liberty 
asthma quest), the reduction of glucocorticoids was 70.1% in 
the dupilumab group, compared to 41.9% in the placebo group. 
Treatment with this mAb resulted in a 59% reduction in severe 
exacerbation rate with an increase in FEV1 of 0.22 L.
66 It is very 
important to note that in this study patients were recruited 
regardless to the presence of type 2 biomarkers, such as 
baseline blood or sputum eosinophil count, FeNO or IgE. These 
aspects confirm the great potential of dupilumab not only in 
Th2 high pattern, but also in neglected phenotypes.
However, some concerns about safety have been raised. An 
increase in the blood eosinophil count up to >3000 cells/μL 
was reported in 13% of the patients,64 including anecdotal 
reports of eosinophilic pneumonia. Type 2 cytokines such as 
IL-4 and IL-13 have been shown to prime migratory responses 
of the hematopoietic progenitor cells (HPC). Consequently, 
the increase of blood eosinophilia could be explained by 
the blocking of the IL4 and IL13 receptor with loss of lung-
homing of eosinophils.67 Moreover, as Th2 cytokines are 
powerful suppressors of IL-17 driven-inflammation, Th2-
targeted treatment may lead to the amplification of the 
activity of the opposite Th17 pathway, limiting therapeutic 
efficacy over time.68 Large-scale studies are needed to clarify 
long-term safety issues. Recently, the United States Food and 
Drug Administration (FDA) approved dupilumab for groups 
of uncontrolled asthma patients, those with eosinophilic 
moderate-to-severe asthma phenotype, even those with oral 
corticosteroid-dependent asthma, regardless of phenotype 
(https://www.accessdata.fda.gov/scripts/cder/daf).
Ongoing research: failures, 
promises, and unmet needs
Ligelizumab (QGE031), a new anti-IgE mAb, showed at the 
first phases of its development higher suppression of free IgE 
when compared to omalizumab; the same effect was observed 
also in patients with very high IgE levels.69 Despite promising 
initial data, the phase 2 study CQGE031B2201 did not satisfy 
the primary outcome, as the superiority of QGE031 compared 
to placebo (Novartis Pharmaceuticals, unpublished data) 
was not demonstrated.70 Nevertheless, according to another 
double-blind RCT parallel groups results, ligelizumab was 
more effective than omalizumab in terms of skin test positivity 
suppression and lung function response, demonstrating its 
potentiality beyond omalizumab.71 However, the development 
of ligelizumab has been currently suspended.
Type 2 immunity is regulated by several transcription factors, 
such as GATA-3, STAT-6, NFAT, IRF4, and c-maf. GATA-3 is one 
of the six members of the GATA transcription factors family 
and represents the main regulator in Th2 differentiation.72 It 
has been shown to play a key role in mediating the asthmatic 
immune response, by promoting the production of IL-4, IL-5, 
and IL-13.73 Induction of GATA-3 overexpression in T and ILC2 
lymphocytes in experimental models leads to an increased 
allergic airway inflammation.74 It has also been shown that 
at least part of the corticosteroid therapeutic activity in the 
treatment of type 2 inflammation can be attributed to an 
inhibitory effect on the phosphorylation of GATA-3, which 
suppresses nuclear translocation of this transcription factor.75,76
Recent options targeting GATA-3 belong to the new class 
of antisense oligonucleotide therapeutics, the 10–23 DNA 
(deoxyribonucleic acid)zymes (DNAzymes) antisense 
oligonucleotide, which includes SB010.77 By cleaving GATA-3  
mRNA, SB010 reduces specific cytokine production and 
thereby exerts its effect on key features of allergic airway 
inflammation.74 Based on the overall positive results of the 
application of GATA-3 DNAzymes in animal models, phase 
1 and 2 RCTs were recently performed with inhaled SB010 
in patients with uncontrolled allergic asthma and sputum 
eosinophilia. SB010 demonstrated a significant reduction of 
Th2-dependent biomarkers such as sputum eosinophilia, serum 
IL-5, and tryptase levels.73 Further clinical trials are needed in 
order to confirm the clinical efficacy of this promising molecule.
Prostaglandin D2 (PGD2) is a prostanoid produced primarily 
by mastcells in atopic subjects. It exerts a pro-inflammatory 
effect and induces vasodilatation and increased permeability. 
Fevipiprant (QAW039) is a PGD2 antagonist of the chemo-
attractant receptor-homologous molecule expressed on 
Th2 cells (CRTH2). The drug, which can bind receptors on the 
surface of eosinophils, basophils, and T lymphocytes in the 
blood and tissues, inhibits the migration and activation of 
these cells in the airway tissues and blocks the PGD2-driven 
release of the Th2 cytokines.78 RCTs of phase 2 and 3 have been 
performed in patients with refractory allergic asthma, and 
others are in progress. Preliminary data confirm a good safety 
profile, an improvement in asthma control and FEV1, especially 
in patients with more severe obstruction.79 
Lebrikizumab (MILR1444A) is a humanized mAb targeting 
IL-13. In the phase 2 studies, lebrikizumab showed an 
improvement in pulmonary function and in the control of 
severe refractory asthma, only in the subgroup of patients with 
allergic phenotype, including high levels of serum periostin 
and exhaled FeNO.80 Subsequently, two parallel phase 3 RCTs 
were conducted to evaluate the effectiveness and safety of 
lebrikizumab in patients with uncontrolled asthma (LAVOLTA 
I and II). LAVOLTA I met its primary endpoint, showing a 
significant reduction of asthma exacerbations rate in people 
with higher levels of serum periostin or blood eosinophils. This 
study also showed a significant improvement in lung function. 
Unfortunately, LAVOLTA II study did not confirm the same 
results.81 
Tralokinumab is another anti-IL-13 mAb, whose development 
is hampered by the poorly encouraging data emerging from 
two randomized phase 2b trials. In fact, tralokinumab did not 
show any significant reduction in exacerbations or improve 
the Asthma Control Questionnaire (ACQ) score.82 A post hoc 
analysis showed a greater improvement in FEV1 in the group 
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with higher basal IL-13 levels (10 μg/mL), suggesting that 
the presence of residual IL-13 was associated with a higher 
response in FEV1.
83 Optimistically, it is possible that a more 
proper patient selection could improve the drug performance; 
the same issue limited, at the beginning, mepolizumab efficacy 
when administered to asthmatic patients independently of 
their phenotype. Three other randomized phase 2 and 3 RCTs 
(MESOS, STRATOS 1 and 2) have confirmed the ineffectiveness 
of tralokinumab in asthma, speculating that the role of IL-13  
may not be crucial for the control of eosinophilic airway 
inflammation.84 In a recent study, adult patients with mild-to-
moderate asthma not receiving inhaled corticosteroids (ICS) 
therapy were randomized to receive lebrikizumab 125 mg 
SC, placebo SC or montelukast 10 mg orally for 12 weeks.85 
Unfortunately, lebrikizumab did not significantly improve the 
FEV1, probably because the inhibition of IL-13 only did not 
result in an effective modulation of bronchial inflammation. 
Regarding neutrophilic and paucigranulocytic asthma, 
the treatment options are extremely limited in the field 
of biologics, as different molecules failed in achieving the 
primary outcomes. CXCR2-chemokine receptor, a potent 
chemo-attractant that mediates neutrophil migration in the 
airways, represents a target currently under investigation. A 
preliminary study showed a reduction in sputum and blood 
neutrophils and a better asthma control based on ACQ, but 
no significant change in FEV1 was observed in patients with 
severe asthma treated with SCH527123, a CXCR2 antagonist.13 
Further studies assessed the safety and efficacy of AZD5069, 
another CXCR2 antagonist, as add-on therapy in patients with 
severe-uncontrolled asthma.86 Treatment with this CXCR2-
selective antagonist did not reduce the frequency of severe 
exacerbations, thus raising major doubts about the role of 
CXCR2-mediated neutrophil recruitment in severe refractory 
asthma exacerbations and potential clinical benefits.
Recently, stem cell factors and its receptors, including the 
tyrosine kinase inhibitor (KIT), were recently evaluated 
because of their critical role to mast cell homeostasis. Mast 
cells are long-living, tissue-dwelling, hematopoietic effector 
cells that are implicated in the pathobiologic basis of asthma 
and are present in patients with severe asthma, in face of 
glucocorticoid therapy. Their presence correlates with airway 
hyper-responsiveness and asthma severity.87 Imatinib, a 
KIT inhibitor, showed promising results in a RCT, which 
reported decreasing airway hyperresponsiveness, mast-cell 
counts, a small but significant increase in FEV1 and tryptase 
release, thus suggesting a KIT-dependent process and mast 
cells contribution to the pathobiological basis of asthma.88 
Currently, further studies on imatinib in asthma are being 
planned in early clinical trials.
The sialic acid-binding immunoglobulin-like lectins (Siglecs), 
members of the immunoglobulin gene family, are currently 
under evaluation for future studies. They selectively regulate 
early neutrophil recruitment in the lung.89 Siglec-9 is 
expressed by human neutrophils and monocytes, as well as 
by a minority of natural killer cells. These proteins can interact 
with antibodies and glycan ligands resulting in neutrophils 
programmed cell death. In addition, Siglec-E antibody 
administration abolishes neutrophil recruitment in mouse 
models of neutrophil lung inflammation. As neutrophils are 
probably the main cause of the generation and perpetuation 
of inflammation in the non-Th2 endotype, targeting Siglec-9 
could be useful for the treatment of severe asthma and chronic 
obstructive pulmonary disease (COPD).90
Is precision medicine already 
outdated?
Severe asthma is characterized by heterogeneity and 
complexity and is classified according to both phenotypes 
and endotypes approaches. Nowadays, in contrast with the 
classical ‘one size fits all’ approach, precision medicine is based 
on specific biological profiles guided by biomarkers, which 
are useful for the development and selection of targeted 
biological therapies. As the advent of biological therapies 
with omalizumab, we are witnessing a growing interest in the 
identification of new biomarkers potentially useful for the 
selection and treatment guidance of patients. The choice of 
the right drug for the right patient is becoming increasingly 
important, considering the partial overlap between the 
populations eligible for anti-IL-5 mAbs or omalizumab, as 
mentioned earlier.60
Recent advances in the immunological and inflammatory 
asthma pathways have led to the identification of the 
alarmins and the key role in the pathogenesis of asthma. 
The airway epithelium has been shown to play a central role 
in the modulation of complex inflammatory processes.91,92 
The cytokines produced by the epithelium can be released 
following the exposure to pro-inflammatory external stimuli. 
Among these cytokines, the triad IL-25, IL-33, and thymic 
stromal lymphopoietin (TSLP) promotes immune responses 
and are involved in delaying the asthmatic reactions after 
exposure to allergens. TSLP is an epithelial-cell–derived 
cytokine produced after environmental and proinflammatory 
stimuli.93,94 The PATHWAY study further investigated the 
clinical and biological role of TSLP in patients with moderate-
to-severe uncontrolled asthma.95 This was a randomized, 
placebo-controlled, dose-ranging trial for tezepelumab, a fully 
human first-in-class anti-TSLP mAb, where patients with various 
levels of blood eosinophilia were also included. The use of 
tezepelumab at various doses (70 mg every 4 weeks, 210 mg 
every 4 weeks or 280 mg every 2 weeks) showed a reduction 
of the exacerbation rate in the treatment groups of 61%, 71%, 
and 66%, respectively, as compared to the placebo group 
(p<0.001 for all comparisons). The same results were observed 
regardless blood eosinophil count, Th2 status, or FeNO levels at 
enrollment. 
The FDA granted tezepelumab as a ‘breakthrough’ biological 
drug for the treatment of severe asthma, thus speeding up 
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its registration process. A Breakthrough Therapy definition is 
designed to fasten the development and regulatory review of 
drugs that have proven to be effective in respect of a clinically 
significant endpoint compared to available drugs (www.
fdanews.com/articles/188355-fda-awards-astrazeneca-and-
amgens-tezepelumab-breakthrough-designation).
The favorable response to this promising drug, almost 
completely independent of the patient phenotyping, could 
provocatively overcome the classic ‘tailored therapy’ or 
‘precision medicine’ paradigm. However, further and much 
larger studies are needed to confirm these findings.
Developments in related diseases 
In COPD, as well as in asthma, there are several inflammatory 
phenotypes. So far, acceptable results have only been obtained 
in the eosinophilic ones. In subjects with moderate-to-severe 
COPD and blood eosinophil counts of 300 cells/μL or greater, 
a major risk of exacerbations and steroids responsitivity is 
reported.96 Two phase 3 RCTs on mepolizumab as add-on 
therapy in patients with eosinophilic COPD (METREX and 
METREO)96 showed interesting findings. Patients with a blood 
eosinophil count of 150 cells/μL or more at screening, or 
300 cells/μL or higher during the previous 12 months were 
included. The results demonstrated a significant reduction 
(23%) of exacerbations in 25% of patients with a baseline 
blood eosinophil count at 300 cells/μL. The clinical efficacy was 
observed only in the 70% of the severe exacerbations treated 
with OCS.
A RCT with benralizumab, including patients with COPD and 
blood eosinophil higher than 300 cells/μL, is ongoing.97 A 
phase 3 study investigating lebrikizumab is also recruiting 
patients; however, given the disappointing results on severe 
asthma, there will probably be no favorable outcome in COPD 
either.81
Chronic rhinosinusitis, both CRS with nasal polyposis (CRSwNP) 
and without nasal polyposis (CRSsNP) is an inflammatory 
disease of the nose and paranasal sinuses, characterized by 
elevated levels of IL-5, IL-13, and eosinophils. In a randomized, 
double-blind, placebo-controlled study, omalizumab 
demonstrated positive results in patients with CRSwNP, even 
in non-allergic patients.98 A recent study in a real-life setting 
confirmed the efficacy of omalizumab in severe allergic asthma 
with co-existent CRSwNP.99 This is probably due to the presence 
of a local mucosal production of IgE. Regarding the anti-IL-5 
mAbs, mepolizumab, and reslizumab, excellent results have 
been demonstrated especially in patients with eosinophilic 
nasal polyps, whereas nasal IL-5 levels did not predict a good 
response.40,100 Another biologic drug, benralizumab, may 
have the advantage of not targeting only eosinophilia but 
basophils, present at high levels in patients with CRSwNP.101 It 
will be necessary to verify through large-scale studies the real 
efficacy of benralizumab and its theoretical superiority over 
competitors.
A phase 2 study (ClinicalTrials.gov identifier: NCT01920893) 
demonstrated the efficacy of dupilumab in reducing nasal polyps 
when added to mometasone furoate nasal spray.102 Significant 
improvements were also observed for the SinoNasal Outcome 
test for sense and smell. Two RCTs are currently underway to 
evaluate the efficacy of this mAb in reducing the severity of nasal 
congestion/obstruction and endoscopic nasal polyp score (NPS) 
(ClinicalTrials.gov identifier: NCT02912468 and NCT02898454).
Economic burden of asthma and 
biological therapies
Asthma is a growing public health problem and the costs of 
management and treatment are increasing. Clinical trials have 
demonstrated that the control of severe asthma, which can 
be achieved through innovative therapies, can reduce the 
overall economic burden, even if the single cost of the drug 
increases.103 It is also shown that the cost of asthma significantly 
increases with the reduction of disease control. However, it is 
possible to obtain important savings on direct costs through 
the correct management of patients and the appropriate use of 
new therapeutic options.104
Because of the economic impact and significant increase of 
direct costs, the availability of new treatment options for severe 
asthma, such as omalizumab, bronchial thermoplasty (BT), and 
mepolizumab, has required great attention in the selection and 
management of potentially eligible patients. Moreover, in some 
countries, drug-economic analyses (CEAs) are necessary as a 
requirement to obtain the reimbursement of biological drugs, 
due to their high cost.
The most considered outcomes of the published studies 
included exacerbations, mortality, health-related quality of life 
(HRQoL), use of healthcare resources, and direct costs. Most 
of the studies on omalizumab conclude that anti-IgE mAb 
achieves clinical outcomes especially when administered in 
patients with difficult-to-treat asthma. This drug is cost effective 
according to the majority of studies, especially if targeted 
to very severe subgroups and with price discounts.105 Direct 
costs could be partly offset by the reduction of the expenses 
incurred by the health service (e.g. hospitalizations), a reduction 
of indirect costs and improvement of quality of life.106,107
Regarding mepolizumab, there are few pharmacoeconomic 
data because of its recent introduction in clinical practice. 
An interesting CEA conducted by the ICER Group was based 
on a simulation model of asthma outcomes and costs in a 
representative population of patients eligible to mepolizumab 
therapy.108 The incremental cost effectiveness of mepolizumab 
was evaluated by gathering drug cost estimates derived 
from current prices and estimates of reductions in asthma 
exacerbations and OCS use from relevant clinical trial data. 
According to the authors of this analysis, based on current 
acquisition prices, the cost-effectiveness estimates are 
unfavorable, as they exceed the commonly cited thresholds. 
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Further doubts arise from the lack of clinical trials evaluating 
the long-term benefits. To obtain a value correlated to the 
clinical benefit, a discount of two-thirds to three-quarters from 
the current price list of mepolizumab would be necessary.
A recent study investigated the potential cost effectiveness of 
mepolizumab.109 A Markov model was used to determine the 
incremental cost per quality of life-year (QALY) obtained for 
mepolizumab plus standard of care (SoC) and for SoC alone. The 
population, including adults with severe eosinophilic asthma, 
was defined on a lifetime horizon. Based on the results of this 
study, to achieve a cost-effectiveness of about $150,000 for QALY, 
mepolizumab would require a discount of over 60% on the price.
So far, only one study aimed at investigating whether 
reslizumab can be cost effective. The authors used a Markov 
model to compare the cost effectiveness of add-on reslizumab 
with the standard of care from the US societal perspective over 
a 5-year time horizon. The conclusion was that the improvement 
in QoL and exacerbation rate with reslizumab is associated with 
high costs, making reslizumab unlikely to be cost-effective at 
the $200,000 willingness-to-pay (WTP) threshold.110 
Another study defined and compared the cost-effectiveness of 
the newest medical treatment strategies for severe refractory 
asthma, such as omalizumab, mepolizumab, and BT.111 The 
authors used a model including a hypothetical cohort of 10,000 
patients with a 10-year horizon. In patients who are responders 
to biological treatment, the addition of bronchial thermoplasty 
was not cost-effective. Mepolizumab without BT was the most 
cost-effective option for biological responders. However, BT 
proved to be a cost-effective treatment option in the group of 
nonresponders to biologicals.
Conclusions
Nowadays, much more than in the past, pharmacological 
research has promised safe and effective therapeutic options 
for patients with severe, uncontrolled asthma, a very complex 
and heterogeneous entity. It should not be neglected that the 
management of severe asthma still represents a challenge, 
because the asthma mortality rate is still unacceptable,112 and 
because poor adherence to therapy was demonstrated not 
only in patients with mild symptoms, but also in those with 
higher levels of severity.113 Furthermore, acute and chronic 
side effects still have a major impact in those patients taking 
OCS treatment. Moreover, the associated costs, especially in 
patients that are unfit for treatment with biological drugs, are 
high.114,115 Some new and effective therapeutic options, such 
as dupilumab, will soon be available, and this will probably 
increase the direct costs associated with pharmacological 
treatment. Understanding the disease mechanisms and 
using predictive biomarkers will allow customization of the 
approach to disease management and will guide the clinician 
in the choice of right drug, among the increasingly numerous 
therapeutic options. It will reduce the number of uncontrolled 
patients and avoid therapeutic failures. The presence of 
overlapping target populations for omalizumab and anti-IL-5 
requires an increasing effort in understanding the differences 
among the underlying pathways of these molecules. It is 
increasingly clear that omalizumab remains the gold standard 
for refractory allergic asthma, especially for the ‘early onset’ 
phenotype, while anti-IL-5 mAbs are indicated in eosinophilic 
asthma with comorbidities such as nasal polyposis. Among the 
latter, benralizumab seems to have a small advantage linked 
to its peculiar mechanism of action, to its rapid onset of effect, 
and to the greater steroid-sparing effect, as discussed earlier. 
Beyond indirect evaluations, comparative head-to-head studies 
will be essential to allow a correct treatment choice and to 
avoid empirical or marketing-oriented selection strategies. 
However, non-Th2 endotype asthma remains a major 
challenge, as research has not provided so far many treatment 
options. In the future, the phenotype will obtain the focus it 
deserves.
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